Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
KSP-1007 by Sumitomo Pharma for Ventilator Associated Pneumonia (VAP): Likelihood of Approval
KSP-1007 is under clinical development by Sumitomo Pharma and currently in Phase I for Ventilator Associated Pneumonia (VAP). According to...
DSP-0390 by Sumitomo Pharma for Oligodendroglioma: Likelihood of Approval
DSP-0390 is under clinical development by Sumitomo Pharma and currently in Phase II for Oligodendroglioma. According to GlobalData, Phase II...
DSP-0390 by Sumitomo Pharma for Anaplastic Astrocytoma: Likelihood of Approval
DSP-0390 is under clinical development by Sumitomo Pharma and currently in Phase II for Anaplastic Astrocytoma. According to GlobalData, Phase...
DSP-1083 by Sumitomo Pharma for Parkinson's Disease: Likelihood of Approval
DSP-1083 is under clinical development by Sumitomo Pharma and currently in Phase II for Parkinson's Disease. According to GlobalData, Phase...
KSP-1007 by Sumitomo Pharma for Complicated Intra-Abdominal Infections: Likelihood of Approval
KSP-1007 is under clinical development by Sumitomo Pharma and currently in Phase I for Complicated Intra-Abdominal Infections. According to GlobalData,...
DSP-3456 by Sumitomo Pharma for Treatment Resistant Depression: Likelihood of Approval
DSP-3456 is under clinical development by Sumitomo Pharma and currently in Phase I for Treatment Resistant Depression. According to GlobalData,...
SMP-3124 by Sumitomo Pharma for Solid Tumor: Likelihood of Approval
SMP-3124 is under clinical development by Sumitomo Pharma and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Sumitomo Pharma's Rodatristat Ethyl?
Rodatristat Ethyl is a small molecule commercialized by Sumitomo Pharma, with a leading Phase I program in Idiopathic Pulmonary Fibrosis....